UBS Group reissued their sell rating on shares of Johnson Matthey (LON:JMAT) in a research note released on Friday, investing.thisismoney.co.uk reports. The firm currently has a GBX 2,750 ($35.93) price target on the stock, down from their previous price target of GBX 3,000 ($39.20).
A number of other research firms have also weighed in on JMAT. Liberum Capital reiterated a buy rating and issued a GBX 4,000 ($52.27) target price on shares of Johnson Matthey in a research note on Thursday, July 26th. Deutsche Bank reiterated a buy rating and issued a GBX 4,500 ($58.80) target price on shares of Johnson Matthey in a research note on Thursday. Berenberg Bank reiterated a buy rating and issued a GBX 4,300 ($56.19) target price on shares of Johnson Matthey in a research note on Monday, September 17th. Finally, Credit Suisse Group reiterated an outperform rating on shares of Johnson Matthey in a research note on Thursday, August 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. Johnson Matthey has an average rating of Buy and a consensus price target of GBX 3,827.78 ($50.02).
LON:JMAT traded up GBX 11 ($0.14) during midday trading on Friday, hitting GBX 3,058 ($39.96). 842,915 shares of the company traded hands, compared to its average volume of 691,012. Johnson Matthey has a 12-month low of GBX 2,681 ($35.03) and a 12-month high of GBX 3,511 ($45.88).
The company also recently declared a dividend, which will be paid on Tuesday, February 5th. Stockholders of record on Thursday, November 29th will be given a dividend of GBX 23.25 ($0.30) per share. This represents a dividend yield of 0.74%. The ex-dividend date is Thursday, November 29th.
In other news, insider Robert MacLeod purchased 12 shares of the company’s stock in a transaction dated Wednesday, November 21st. The shares were acquired at an average price of GBX 3,072 ($40.14) per share, with a total value of £368.64 ($481.69). Insiders have bought a total of 36 shares of company stock worth $116,928 in the last three months.
Johnson Matthey Company Profile
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
Recommended Story: Do You Need a Fiduciary?
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.